Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Medical vs Surgical Treatment for Peritonsillar Abscesses
NCT04998513Withdrawn
- Sponsor
- Nova Scotia Health
- Start
- Jan 2022
- Primary completion
- Jan 2022
- Modality
- Reversible Covalent Inhibitors, Orthosteric Ligands
01
Overview
Randomised, single-blind trial of dexamethasone, cefazolin, metronidazole and probenecid in peritonsillar abscess (PTA), sponsored by Nova Scotia Health. Primary endpoint: Recruitment rate at 1 month. Planned start Jan 2022; status: withdrawn.
02
Drugs
dexamethasonecefazolinmetronidazoleprobenecid
03
Conditions
peritonsillar abscess (PTA)
Beyond the preview
Go deeper on NCT04998513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04998513.